Vention Inc. is a digital manufacturing platform based in Montreal, Canada, that specializes in the design and ordering of custom machines. Founded in 2016, the company offers a cloud-based solution called MachineBuilder 3D™, which allows engineers and manufacturing professionals to design, order, and assemble factory equipment quickly and efficiently. The platform features a comprehensive library of modular parts, enabling users to create automated equipment, robot cells, tooling, and conveyors. Additionally, Vention integrates artificial intelligence to facilitate the design process, allowing for the simulation and commissioning of automated systems within a single digital environment. By streamlining the machine design and ordering process, Vention makes industrial automation more accessible to a wider range of users.
Coin Metrics Inc. is an online publisher specializing in blockchain and cryptocurrency data, offering a range of market and network analytics to various industries. Founded in 2017 and based in Cambridge, Massachusetts, the company provides several key products, including the CM Network Data Pro, which delivers historical crypto network data in a detailed format for institutional clients. Additionally, Coin Metrics offers the CM Market Data Feed, a standardized solution for trade, candle, and order book data from multiple exchanges, and CM Reference Rates, which provides fixed pricing for various assets quoted in U.S. dollars. By focusing on transparent and actionable data, Coin Metrics enables stakeholders to better understand and utilize public crypto networks.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
Menlo Micro, Inc. specializes in the design and development of electronic switches, particularly focusing on electromechanical switch technology. The company's innovative digital-micro-switches are utilized across various industries, including battery management, home automation, electronic vehicles, and medical instrumentation. Their products are engineered to operate effectively under high temperatures and stressful conditions, supporting applications such as high-power tunable resonators, broadband power amplifier impedance matching, and electronically steerable antennas. Menlo Micro also plays a role in advancing the industrial Internet of Things and next-generation 5G mobile networks. Founded in 2016 and based in Irvine, California, the company aims to deliver efficient outcomes through its cutting-edge technology.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Astera Labs, a fabless semiconductor company founded in 2017 and headquartered in Santa Clara, California, specializes in purpose-built connectivity solutions for data-centric systems. The company designs and supplies a range of products, including system-aware semiconductor integrated circuits, boards, and high-speed connectivity solutions. Its portfolio features Aries PCIe smart retimers and various systems such as riser cards and PCIe-over-cable extender cards. These products cater to applications in server connectivity, distributed machine learning, and high-end gaming graphics. Astera Labs collaborates with leading processor vendors and cloud service providers to enhance performance and eliminate bottlenecks in compute-intensive workloads. Additionally, the company offers design and testing services, along with its COSMOS software suite, which supports observability and predictive analytics to meet the demands of hyperscalers and original equipment manufacturers.
Veterinary Emergency Group is dedicated to providing emergency and urgent care for pets, operating a network of veterinary clinics that are accessible during nights, weekends, and holidays. The organization focuses on delivering timely medical care for acute problems, ensuring that animals receive attention when they need it most. With a trained staff specializing in emergency care and equipped with advanced diagnostic tools, Veterinary Emergency Group emphasizes a customer-centered approach, aiming for rapid response times year-round. This commitment allows families to seek immediate assistance for their pets during critical situations.
Redwood Materials, Inc. is a recycling and materials processing company based in Carson City, Nevada, founded in 2017. The company specializes in developing sustainable methods for recycling various metals and materials, particularly from batteries and electronics, to support circular supply chains. Its focus includes lithium, nickel, copper, gold, silver, cobalt, and other critical elements used in electric vehicles, renewable energy storage, and consumer electronics. By providing environmentally sound recycling solutions, Redwood Materials aims to address the increasing demand for battery end-of-life management as the number of electric vehicles rises globally. The company's innovative technology not only recycles waste but also generates essential raw materials, enabling manufacturers to create sustainable products and significantly contributing to the transition towards a circular economy.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.
Tenstorrent Inc. is a technology company that develops and manufactures application-specific integrated circuits (ASIC) designed for machine learning and hardware applications. Founded in 2016 and headquartered in Toronto, Canada, with an additional office in Austin, Texas, Tenstorrent's architecture is engineered for use in a range of devices, from battery-powered Internet of Things (IoT) devices to large cloud servers. The company aims to enhance performance and efficiency for artificial intelligence workloads by co-designing hardware, software, and AI algorithms. Its processors are characterized by scalability, programmability, and improved flexibility compared to traditional accelerators like CPUs and GPUs. Tenstorrent's team comprises experts in computer architecture, hardware design, systems engineering, and machine learning, positioning the company to support advancements in technology across various industries.
ASAPP, Inc. develops artificial intelligence-native products designed to address large-scale inefficiencies in customer care and sales processes. Its primary offering is an AI-native platform that empowers agents by providing real-time guidance on communication and actions during customer interactions, whether through phone calls or digital messages. The platform utilizes advanced machine learning models that continuously adapt and learn from each interaction, effectively enhancing agent performance without necessitating extensive training. ASAPP serves major industries, including telecom, financial services, and travel, and has established a global presence with offices in New York, San Francisco, Mountain View, London, Buenos Aires, Ithaca, and Raleigh. Founded in 2014, the company aims to transform the way organizations manage customer engagement through innovative technology solutions.
ASAPP, Inc. develops artificial intelligence-native products designed to address large-scale inefficiencies in customer care and sales processes. Its primary offering is an AI-native platform that empowers agents by providing real-time guidance on communication and actions during customer interactions, whether through phone calls or digital messages. The platform utilizes advanced machine learning models that continuously adapt and learn from each interaction, effectively enhancing agent performance without necessitating extensive training. ASAPP serves major industries, including telecom, financial services, and travel, and has established a global presence with offices in New York, San Francisco, Mountain View, London, Buenos Aires, Ithaca, and Raleigh. Founded in 2014, the company aims to transform the way organizations manage customer engagement through innovative technology solutions.
Wasabi Technologies, Inc. is a cloud storage provider that offers a fast and cost-effective platform for hybrid and multi-cloud media workflows. The company specializes in hot storage solutions compatible with Amazon S3, delivering average time-to-first-byte speeds of less than 15 milliseconds and ensuring data integrity with active checking. Wasabi's services support a variety of applications, including archiving, backup and recovery, content delivery, and data analytics, catering to sectors such as media and entertainment, education, healthcare, and law enforcement. The company provides a free trial capped at 1 TB of storage and offers flexible pricing options, ensuring that organizations can access secure and reliable data storage without complex pricing structures or unpredictable fees. Founded in 2016 and headquartered in Boston, Massachusetts, Wasabi was previously known as BlueArchive, Inc. before rebranding in 2017.
Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.
Emalex Biosciences is a biopharmaceutical company focused on developing innovative treatments for patients suffering from central nervous system disorders, particularly those with limited or no existing treatment options. The company is advancing its investigational medicine, ecopipam, aimed at addressing fluency disorders and Tourette Syndrome. Emalex also collaborates with patient advocacy organizations and medical researchers to enhance the understanding and treatment of rare neurological conditions. Through its efforts, the company seeks to provide effective solutions for individuals affected by these challenging disorders.
ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Rad Power Bikes LLC is a Seattle-based manufacturer of electric bicycles, established in 2015. The company specializes in designing and selling feature-rich e-bikes intended for both on and off-road use, focusing on comfort and utility. Rad Power Bikes operates a direct-to-consumer model, enabling customers to purchase their products online at competitive prices. In addition to electric bicycles, the company offers a range of accessories, including storage bags, fenders, racks, and safety products, as well as replacement parts such as batteries and tires. Rad Power Bikes is committed to making sustainable transportation accessible to a wide audience.
Vera Therapeutics is engaged in the development of innovative gene editing solutions aimed at curing genetic diseases, particularly sickle cell disease and cystic fibrosis. The company utilizes a proprietary triplex gene editing platform to create a pipeline of therapeutic products targeting high-penetrance disease genes. Founded in 2016 and based in South San Francisco, California, Vera Therapeutics is dedicated to alleviating and potentially curing genetic disorders in affected patients.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the manufacture of self-driving vehicles designed for local goods transportation. Incorporated in 2016, Nuro focuses on transforming local commerce through autonomous delivery services. The company operates a fleet of electric, fully autonomous vehicles capable of delivering a wide range of products, from food to pharmaceuticals. Nuro's mission is to enhance everyday life by providing quick, affordable, and safe delivery solutions for merchants and their customers.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.
Prelude Therapeutics is a clinical-stage biopharmaceutical company based in Wilmington, Delaware, founded in 2016. The company focuses on discovering and developing small molecule therapies designed to target critical mechanisms driving cancer growth and resistance. Its pipeline includes several candidates currently in Phase 1 clinical trials, such as PRT543, aimed at treating solid tumors and myeloid malignancies, and PRT811, which targets solid tumors like glioblastoma multiforme. Other development programs include PRT1419, a selective inhibitor of an anti-apoptotic protein, PRT2527, an inhibitor of CDK9, PRT-SCA2 for genomically selected cancers, and PRT-K4 for solid tumors. Prelude Therapeutics aims to provide innovative treatment options for patients facing refractory cancers.
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.
ApplyBoard is an online platform that facilitates access to education for international students by connecting them with academic institutions and recruitment partners. Established in 2015 and headquartered in Kitchener, Ontario, the company has grown to employ over 500 staff members across 20 countries. ApplyBoard has formed partnerships with more than 1,200 educational institutions and collaborates with over 4,000 recruitment partners to promote diversity and attract qualified applicants to campuses in Canada, the United States, and the United Kingdom. Since its inception, ApplyBoard has assisted over 120,000 students in navigating the educational application process, making it easier for them to pursue their studies abroad.
Alignment Healthcare is dedicated to transforming the complex and confusing process of medical treatment so that every link in the healthcare continuum becomes more efficient, productive and effective. The company partners with providers, health plans and hospitals to create a seamless, fast and easy-to-navigate healthcare experience, which results in happier, healthier and more satisfied patients. Based in Irvine, California, Alignment Healthcare provides partners with an end-to-end continuous care program, including clinical care coordination, risk management capabilities, and IT enablement
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Allbirds, Inc. is a San Francisco-based company founded in 2015 that specializes in manufacturing eco-friendly footwear and apparel. The company offers a range of products, including wool runners, tree runners, tree loungers, tree skippers, and insoles for men, women, and children. Allbirds is committed to sustainability, utilizing premium natural materials to create comfortable and well-designed shoes that align with its mission of reducing environmental impact. The brand distinguishes itself by emphasizing thoughtfulness over flash in the footwear industry. Products are sold through a combination of physical stores and online platforms, with a significant portion of revenue generated from sales within the United States.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
Kaleido Biosciences is a clinical-stage healthcare company based in Lexington, Massachusetts, dedicated to developing microbiome metabolic therapies (MMTs) aimed at treating various diseases and improving human health. Founded in 2015, the company is advancing a diverse pipeline of MMT candidates targeting conditions such as urea cycle disorders, hepatic encephalopathy, multi-drug resistant infections, cardiometabolic and liver diseases, and immune oncology. Kaleido employs a unique, chemistry-driven approach to harness the microbiome's potential, focusing on modulating its metabolic output and profile by influencing the existing microbial functions. The company has established collaborations with notable institutions, including Gustave Roussy Cancer Center and Washington University School of Medicine, to further explore the applications of MMTs in immuno-oncology and other health conditions.
Cibus is a biotechnology company specializing in advanced breeding technologies that create non-transgenic plants, meaning they do not incorporate foreign genetic material. The company has developed a proprietary gene-editing technology known as the Rapid Trait Development System, which combines crop-specific cell biology with various gene editing techniques. Cibus focuses on developing traits that enhance agricultural productivity by addressing challenges such as disease resistance, pest control, weed management, nutrient use, and climate adaptation. Its first commercial product, SU Canola™, has been launched in North America, with plans to introduce non-transgenic traits across all major crops.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
Atom Tickets, LLC is a technology company based in Santa Monica, California, that operates a mobile application for Android and iOS designed to simplify the movie-going experience. The app enables users to find and purchase movie tickets and concessions, order food in advance, and coordinate ticket payments for group outings. With features that include movie reviews, trailers, and synopses, the application assists users in selecting films. Additionally, it allows for group seating arrangements while enabling separate payment for each ticket, eliminating the need for paper tickets and lengthy discussions about plans. Originally founded as MovieFriends, LLC in 2012, the company rebranded to Atom Tickets in July 2016.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action.
The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Wheels Up is a membership-based private aviation company that focuses on reducing the upfront cost to fly privately, providing flexibility, service, and safety. Its mobile app enables members to book flights, manage their accounts, and participate in ride-share opportunities. Its members also have given access to the Wheels Down program. The company was founded in 2013 and headquartered in New York, United States.
Reddit is a social media platform that facilitates online communities where users can submit links, create content, and engage in discussions on a wide array of topics. Launched in 2005 and operated from San Francisco, Reddit allows users to post links to content, which can be voted up or down by others, influencing the visibility of these posts on the site’s homepage. Users can also comment on posts, with comments subject to similar voting dynamics. This system rewards users with "karma" points for submitting popular content. The platform is organized into various topical sections known as subreddits, which cover specific interests such as programming, science, and politics. Reddit aims to foster community engagement and discourse across diverse subjects.
Spring is a retail company that offers a diverse selection of products, including apparel and home and garden items. It operates as a shopping application designed for iOS devices, allowing users to follow their favorite brands and purchase new arrivals, exclusives, and unique products. Originally founded as Jello Labs, the company rebranded to Spring in July 2014. The founders of Spring are David Tisch, Alan Tisch, and Octavian Costache, and the company is based in New York.
Home Dialysis Plus, Ltd. provides home hemodialysis solutions to patients and their healthcare providers. Its dialysis system enables hemodialysis treatment in the homes of patients. Home Dialysis Plus, Ltd. was founded in 2003 and is based in Portland, Oregon.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
10X Genomics is a life science technology company that specializes in developing and selling instruments, consumables, and software for analyzing biological systems. Headquartered in Pleasanton, California, the company offers a range of products, including chromium instruments, microfluidic chips, reagents, and other consumables. Its advanced single-cell solutions allow researchers to measure gene expression, immune profiling, epigenetics, and cellular heterogeneity, providing insights into the physical organization of DNA and gene activity on a cell-by-cell basis. Additionally, the Visium spatial gene expression solution enables the measurement of spatial gene expression patterns across tissue samples. 10X Genomics serves a diverse clientele, including academic institutions, government agencies, and biopharmaceutical companies, and has a presence in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was founded in 2012 and rebranded from 10X Technologies, Inc. in November 2014.
Magic Leap is a US-based startup specializing in augmented reality (AR) technology that aims to transform user interaction with digital devices. The company develops a mixed reality computing platform that merges the digital and physical worlds through advanced three-dimensional imagery. Its proprietary headset utilizes Dynamic Digitized Lightfield Signal technology to create images that are indistinguishable from real objects, seamlessly integrating them into the user's environment. By combining users' natural visual capabilities with mobile computing, Magic Leap offers a unique AR experience that redefines how individuals engage with screens and visualize data. The system is designed to harmonize with human senses, allowing for an immersive and visually cinematic interaction with digital content.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
Handy Technologies, Inc., doing business as Handy, operates an online platform for connecting individuals looking for household services with independent service professionals. It offers repair and maintenance services, which includes air conditioner services, furniture assembly services, plumbing services, electrical services, and home cleaning services. Handy Technologies, Inc. was formerly known as Handybook, Inc. and changed its name to Handy Technologies, Inc. in September 2014. The company was founded in 2012 and is based in New York, New York having additional offices in Boston, Chicago, London, Los Angeles, San Francisco, Toronto, and Vancouver. Handy Technologies, Inc. operates as a subsidiary of ANGI Homeservices Inc.
Bracket Computing Inc. develops advanced workload isolation software aimed at enhancing security for enterprises operating in hybrid cloud environments. Founded in 2011 and based in Mountain View, California, the company provides a platform that features crypto-enforced micro-segmentation, ensuring that data is always encrypted both at rest and in motion. Users maintain control over encryption keys while benefiting from data integrity monitoring and forensic capabilities that capture memory at the moment of a breach. Bracket Computing's solutions are designed to prevent the spread of malware and insider threats without compromising the efficiency and agility of cloud operations, thereby safeguarding enterprise systems from external attacks.
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.
Made.com Design Limited designs, manufactures, and distributes furniture. It offers sofas and armchairs, including corner and modular sofas, sofa beds, leather sofas, and chaises; floor, table, wall, and desk lamps; ceiling lights; pendant caps and shades; and dining, coffee, side, bedside, dressing, extending, console, and outdoor tables, as well as desks and television stands. The company also provides dining, accent, office, high back, and outdoor chairs; stools, ottomans, and footstools; love seats; bean bags and benches; and bookcases and shelves, media units, chests of drawers, wardrobes, storage benches, sideboards, cabinets, bedside and storage tables, and bins. In addition, it offers mattresses and bed linen; accessories, including arts, cushions, clocks, throws and blankets, coat stands and hooks, mirrors, and rugs; and bed sets and sheets, bath towels and mats, and bedspreads and blankets. Further, it provides storage and bedding products, beds, tables and chairs, bunk beds, desks, and accessories for kids. It sells its products through its showrooms and through Internet. The company was founded in 2009 and is based in London, United Kingdom.
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.
PAX Labs, Inc. specializes in the manufacture of high-quality, app-controlled vaporizers for loose-leaf and concentrated substances. The company's product line includes the PAX 3, PAX 2, and PAX Era, along with a variety of accessories designed to enhance the user experience. PAX also provides a mobile application that allows users to customize their vaporization experience, promoting quality and transparency in cannabis consumption. Founded in 2004 and based in San Francisco, California, PAX Labs has established itself as an industry leader through innovation and thoughtful design. The company distributes its products through a network of retailers and distributors both domestically and internationally, as well as through its online platform.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Blue Bottle Coffee is a coffee roaster and retailer platform that delivers coffee subscriptions to doorsteps nationwide. Blue Bottle Coffee is a passionate team of hundreds around the world, united by the simple purpose of getting great coffee to everyone who asks for it whether that be in our cafes or at home. Blue Bottle is headquartered in Oakland, California, and has retail and business operations in the Bay Area, Los Angeles, New York, and Tokyo.
Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.
Hootsuite Media Inc. operates a leading social media management platform that enables organizations to manage their social media presence across various networks from a single, integrated dashboard. Founded in 2008 and headquartered in Vancouver, Canada, Hootsuite serves over 15 million users, including more than 800 Fortune 1000 companies. The platform provides tools for scheduling posts, managing content, measuring performance, and organizing social streams, as well as offering educational resources and certification programs. Hootsuite features several plans tailored for different users, including a free option for personal use, a Pro plan for small businesses, and an Enterprise plan for larger organizations. The company also offers specific tools such as Hootlet for link shortening and Google My Business integration for managing customer interactions. Hootsuite caters to various industries, including finance, government, healthcare, and education, and has a global presence with offices in major cities around the world.
Manthan is a leading cloud analytics company for consumer facing businesses. We excel in the application of decision sciences, advanced math and artificial intelligence and have a restless ability to invent and bring ideas to life. Manthan’s analytics solutions are powered by AI, cloud and prescriptive capabilities. They are unique in their ability to use machine intelligence to process every decision context and respond automatically with actions and recommendations to manage every aspect of a consumer business, whether its marketing, merchandising, channel/store, demand or supply. Manthan’s inventions aim to bring a new paradigm of context-aware, automated and algorithmic business decisions and actions, executed at scale.
Kobo offers an open platform for e-reading. The platform supports many formats, including EPUB and PDF, and allows its readers to buy and read digital content from a variety of sources. Kobo offers an eBook store with nearly 4 million titles across 68 languages, varying from bestsellers, self-published works, and magazines to kids’ books. It provides e-reader apps for Apple, BlackBerry, Android, and Windows platforms. Bookmarks synchronize across devices so the readers can pick up where they left off from one device to another. Kobo offers its digital reading experience to millions of readers around the world in 190 countries through its website, bookseller, and retail partner network, represented by 17,600 locations around the world. Kobo was founded in 2009 and is based in Toronto, Ontario.
Zynga Inc. is a prominent developer and operator of social games, offering live services that are accessible on mobile platforms and social networking sites. Founded in 2007 and headquartered in San Francisco, California, Zynga markets popular game franchises, including Slots, Words With Friends, Zynga Poker, and FarmVille. The company's games are available on platforms such as iOS, Android, Facebook, and Snapchat. Zynga generates revenue primarily through mobile game downloads and in-game sales of virtual goods, with a significant portion also coming from advertising services provided to agencies and brokers. The majority of its revenue is derived from online gaming, with its top three games contributing substantially to this segment. Zynga's focus on engaging users through social gaming continues to position it as a leader in the interactive entertainment industry.
BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.
Exit41's Software as a Service (SaaS) social ordering solutions have processed over twenty million food orders for consumers on behalf of leading restaurant brands across the globe including Qdoba Mexican Grill, la Madeleine, Cara Operations, Americana Group and Lettuce Entertain You Enterprises. Exit41's web and mobile applications enable restaurants to connect with, recognize and reward their customers and build loyal, profitable relationships. Founded in 1999, Exit41 is headquartered in Andover, Massachusetts, and is backed by tier one investors including GrandBanks Capital and Dace Ventures.
Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.
Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.